Lead Product(s) : DNL747
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Denali Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 28, 2018
Lead Product(s) : DNL747
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Denali Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate DNL747 in Subjects With Alzheimer's Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 28, 2018